A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336
This study is recruiting at 12 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Diabetes Mellitus, Type 2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 10 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Stamford Therapeutics Consortium · Stamford, CT
Georgia · 1
- CenExel iResearch, LLC · Decatur, GA
Idaho · 1
- Medical Research Partners · Ammon, ID
Kansas · 1
- Cotton O'Neil Diabetes & Endocrinology · Topeka, KS
New York · 1
- Advantage Clinical Trials · The Bronx, NY
Oklahoma · 1
- Central States Research · Tulsa, OK
Pennsylvania · 1
- Frontier Clinical Research, LLC · Smithfield, PA
Texas · 5
- Gadolin Research · Beaumont, TX
- Driscoll Children's Hospital · Corpus Christi, TX
- Proactive Clinical Research LLC · Edinburg, TX
- Consano Clinical Research, LLC · Shavano Park, TX
- Victoria Clinical Research Group · Victoria, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.